共查询到20条相似文献,搜索用时 31 毫秒
1.
Lang Jiang Lingyun Ren Xin Guo Jing Zhao Hao Zhang Shanshan Chen Sheng Le Hao Liu Ping Ye Manhua Chen Jiahong Xia 《International journal of biological sciences》2021,17(9):2193
The functions of dual-specificity phosphatase 9 (DUSP9) in hepatic steatosis and metabolic disturbance during nonalcoholic fatty liver disease were discussed in our prior study. However, its roles in the pathophysiology of pressure overload-induced cardiac hypertrophy remain to be illustrated. This study attempted to uncover the potential contributions and underpinning mechanisms of DUSP9 in cardiac hypertrophy. Utilizing the gain-and-loss-of-functional approaches of DUSP9 the cardiac phenotypes arising from the pathological, echocardiographic, and molecular analysis were quantified. The results showed increased levels of DUSP9 in hypertrophic mice heart and angiotensin II treated cardiomyocytes. In accordance with the results of cellular hypertrophy in response to angiotensin II, cardiac hypertrophy exaggeration, fibrosis, and malfunction triggered by pressure overload was evident in the case of cardiac-specific conditional knockout of DUSP9. In contrast, transgenic mice hearts with DUSP9 overexpression portrayed restoration of the hypertrophic phenotypes. Further explorations of molecular mechanisms indicated the direct interaction of DUSP9 with ASK1, which further repressed p38 and JNK signaling pathways. Moreover, blocking ASK1 with ASK1-specific inhibitor compensated the pro-hypertrophic effects induced by DUSP9 deficiency in cardiomyocytes. The main findings of this study suggest the potential of DUSP9 in alleviating cardiac hypertrophy at least partially by repressing ASK1, thereby looks promising as a prospective target against cardiac hypertrophy. 相似文献
2.
Fangfang Li Yiming Yang Chuanyou Xue Mengtong Tan Lu Xu Jianbo Gao Luhong Xu Jing Zong Wenhao Qian 《Journal of cellular and molecular medicine》2020,24(22):13383
This study aims to determine the efficacy of Zinc finger protein ZBTB20 in treatment of post‐infarction cardiac remodelling. For this purpose, left anterior descending (LAD) ligation was operated on mice to induce myocardial infarction (MI) with sham control group as contrast and adeno‐associated virus (AAV9) system was used to deliver ZBTB20 to mouse heart by myocardial injection with vehicle‐injected control group as contrast two weeks before MI surgery. Then four weeks after MI, vehicle‐treated mice with left ventricular (LV) remodelling underwent deterioration of cardiac function, with symptoms of hypertrophy, interstitial fibrosis, inflammation and apoptosis. The vehicle‐injected mice also showed increase of infarct size and decrease of survival rate. Meanwhile, the ZBTB20‐overexpressed mice displayed improvement after MI. Moreover, the anti‐apoptosis effect of ZBTB20 was further confirmed in H9c2 cells subjected to hypoxia in vitro. Further study suggested that ZBTB20 exerts cardioprotection by inhibiting tumour necrosis factor α/apoptosis signal‐regulating kinase 1 (ASK1)/c‐Jun N‐terminal kinase 1/2 (JNK1/2) signalling, which was confirmed by shRNA‐JNK adenoviruses transfection or a JNK activator in vitro as well as ASK1 overexpression in vivo. In summary, our data suggest that ZBTB20 could alleviate cardiac remodelling post‐MI. Thus, administration of ZBTB20 can be considered as a promising treatment strategy for heart failure post‐MI.Significance Statement: ZBTB20 could alleviate cardiac remodelling post‐MI via inhibition of ASK1/JNK1/2 signalling. 相似文献
3.
Yasumasa Ikeda Kaori Sato David R. Pimentel Flora Sam Reuben J. Shaw Jason R. B. Dyck Kenneth Walsh 《The Journal of biological chemistry》2009,284(51):35839-35849
LKB1 encodes a serine/threonine kinase, which functions upstream of the AMP-activated protein kinase (AMPK) superfamily. To clarify the role of LKB1 in heart, we generated and characterized cardiac myocyte-specific LKB1 knock-out (KO) mice using α-myosin heavy chain-Cre deletor strain. LKB1-KO mice displayed biatrial enlargement with atrial fibrillation and cardiac dysfunction at 4 weeks of age. Left ventricular hypertrophy was observed in LKB1-KO mice at 12 weeks but not 4 weeks of age. Collagen I and III mRNA expression was elevated in atria at 4 weeks, and atrial fibrosis was seen at 12 weeks. LKB1-KO mice displayed cardiac dysfunction and atrial fibrillation and died within 6 months of age. Indicative of a prohypertrophic environment, the phosphorylation of AMPK and eEF2 was reduced, whereas mammalian target of rapamycin (mTOR) phosphorylation and p70S6 kinase phosphorylation were increased in both the atria and ventricles of LKB1-deficient mice. Consistent with vascular endothelial growth factor mRNA and protein levels being significantly reduced in LKB1-KO mice, these mice also exhibited a reduction in capillary density of both atria and ventricles. In cultured cardiac myocytes, LKB1 silencing induced hypertrophy, which was ameliorated by the expression of a constitutively active form AMPK or by treatment with the inhibitor of mTOR, rapamycin. These findings indicate that LKB1 signaling in cardiac myocytes is essential for normal development of the atria and ventricles. Cardiac hypertrophy and dysfunction in LKB1-deficient hearts are associated with alterations in AMPK and mTOR/p70S6 kinase/eEF2 signaling and with a reduction in vascular endothelial growth factor expression and vessel rarefaction. 相似文献
4.
5.
Hui Yang Xiao-Xiao Wang Chun-Yu Zhou Xue Xiao Cui Tian Hui-Hua Li Chun-Lin Yin Hong-Xia Wang 《Journal of cellular and molecular medicine》2020,24(11):6233-6241
The pathogenesis of cardiac hypertrophy is tightly associated with activation of intracellular hypertrophic signalling pathways, which leads to the synthesis of various proteins. Tripartite motif 10 (TRIM10) is an E3 ligase with important functions in protein quality control. However, its role in cardiac hypertrophy was unclear. In this study, neonatal rat cardiomyocytes (NRCMs) and TRIM10-knockout mice were subjected to phenylephrine (PE) stimulation or transverse aortic constriction (TAC) to induce cardiac hypertrophy in vitro and in vivo, respectively. Trim10 expression was significantly increased in hypertrophied murine hearts and PE-stimulated NRCMs. Knockdown of TRIM10 in NRCMs alleviated PE-induced changes in the size of cardiomyocytes and hypertrophy gene expression, whereas TRIM10 overexpression aggravated these changes. These results were further verified in TRIM10-knockout mice. Mechanistically, we found that TRIM10 knockout or knockdown decreased AKT phosphorylation. Furthermore, we found that TRIM10 knockout or knockdown increased ubiquitination of phosphatase and tensin homolog (PTEN), which negatively regulated AKT activation. The results of this study reveal the involvement of TRIM10 in pathological cardiac hypertrophy, which may occur by prompting of PTEN ubiquitination and subsequent activation of AKT signalling. Therefore, TRIM10 may be a promising target for treatment of cardiac hypertrophy. 相似文献
6.
Cardiac myocyte apoptosis underlies the pathophysiology of cardiomyopathy, and plays a critical role in the transition from myocardial hypertrophy to heart failure. Angiotensin II (Ang II) induces cardiac myocyte apoptosis and hypertrophy which contribute to heart failure possibly through enhanced oxidative stress; however, the mechanisms underlying the activation of both pathways and their interactions remain unclear. In the present study, we have investigated whether overexpression of the antioxidant protein heme oxygenase-1 (HO-1) protects against apoptosis and hypertrophy in cultured rat cardiac myocytes treated with Ang II. Our findings demonstrate that Ang II (100 nM, 24 h) alone upregulates HO-1 expression and induces both myocyte hypertrophy and apoptosis, assessed by measuring terminal deoxynucleotidyltransferase dUTP nick-end labelling (TUNEL) staining, caspase-3 activity and mitochondrial membrane potential. Ang II elicited apoptosis was augmented in the presence of tin protoporphyrin, an inhibitor of HO activity, while HO-1 gene transfer to myocytes attenuated Ang II-mediated apoptosis but not hypertrophy. Adenoviral overexpression of HO-1 was accompanied by a significant increase in Ang II induced phosphorylation of Akt, however, Ang II-mediated p38 mitogen activated protein kinase (MAPK) phosphorylation was attenuated. Inhibition of phosphotidylinositol-3-kinase enhanced myocyte apoptosis elicited by Ang II, however, p38MAPK inhibition had no effect, suggesting that overexpression of HO-1 protects myocytes via augmented Akt activation and not through modulation of p38MAPK activation. Our findings identify the signalling pathways by which HO-1 gene transfer protects against apoptosis and suggest that overexpression of HO-1 in cardiomyopathies may delay the transition from myocyte hypertrophy to heart failure. 相似文献
7.
Luyang Yu Wang Min Yun He Lingfeng Qin Haifeng Zhang Anton M. Bennett Hong Chen 《The Journal of biological chemistry》2009,284(20):13481-13488
Previously we have shown that tyrosine 718 of ASK1 when phosphorylated is
critical for SOCS1 binding and SOCS1-mediated degradation of ASK1. However,
the kinase and phosphatase responsible for phosphorylation and
dephosphorylation of ASK1 at Tyr-718 are unknown. In this study, we identified
JAK2 and SHP2 as a Tyr-718-specific kinase and phosphatase, respectively.
Interferon-γ (IFN-γ) induced degradation of ASK1 in normal but not
in SOCS1-KO endothelial cells (EC). IFN-γ-induced tyrosine
phosphorylation of ASK1 at Tyr-718 was blocked by a JAK2-specific inhibitor.
IFN-γ enhanced the association between JAK2 and ASK1, and the ASK1-JAK2
complex was labile and was stabilized by the proteasomal inhibitor MG132.
Furthermore, JAK2, but not JAK1, directly bound to and phosphorylated ASK1 at
Tyr-718, leading to an enhanced association of ASK1 with SOCS1 and subsequent
ASK1 degradation. Next, we showed that overexpression of the SH2-containing
protein-tyrosine phosphatase-2 (SHP2) augmented, whereas a
phosphatase-inactive mutant of SHP2 inhibited, TNF-induced ASK1
dephosphorylation. SHP2 associated with ASK1 in response to tumor necrosis
factor in EC. An SHP-2 substrate-trapping mutant formed a complex with
tyrosine-phosphorylated ASK1, suggesting that ASK1 is a direct SHP2 substrate.
Moreover, SHP2 wild type, but not a catalytically inactive mutant, dissociated
SOCS1 from ASK1. IFN-γ-induced ASK1 Tyr(P)-718 was enhanced in mouse EC
deficient in SHP2 (SHP2-KO). In contrast, tumor necrosis factor-induced
dephosphorylation of ASK1 at Tyr(P)-718 and activation of ASK1-JNK signaling,
as well as EC apoptosis, are significantly reduced in SHP2-KO EC. Our data
suggest that JAK2-SOCS1 and SHP2 reciprocally regulate ASK1 phosphorylation
and stability in response to cytokines.Myocardial infarction due to atherosclerosis of coronary arteries remains
the leading cause of death in the United States. It has become clear that
increases in inflammatory mediators represent a common pathogenic mechanism
for atherosclerosis (1). The
vascular cell that normally limits the inflammatory and atherosclerotic
process is the EC.3
Proinflammatory stimuli induce EC dysfunction, which is characterized by an
enhanced sensitivity of vascular cells to proinflammatory and proapoptotic
stimuli. Studies from our laboratory and others have demonstrated that ASK1
(apoptosis signal-regulating kinase-1), a member of MAP3K family
(2,
3), is an effector of
inflammation in EC
(4–8).
Almost all inflammatory stimuli such as tumor necrosis factor-α (TNF),
interleukin-1 (IL-1), and reactive oxygen species activate ASK1. Activated
ASK1 subsequently recruits and activates its downstream target MAP2Ks (MKK3/7
and MKK4/7), which in turn activate MAPKs (JNK and p38). Studies from
ASK1-deficient mice have also linked ASK1 to cardiovascular pathogenesis. ASK1
deletion in mice attenuated angiotensin II-induced cardiac hypertrophy and
remodeling. Neointimal formation due to proliferation of smooth muscle cells
in a cuff injury model is also attenuated by ASK1 deletion in mice
(9,
10).Although the linkage of ASK1 to inflammation is very strong, the mechanism
by which inflammatory stimuli, including TNF, activate ASK1 is not fully
understood. The identification of proteins associated with ASK1 and their
regulation on ASK1 have provided some insights into the mechanism for ASK1
activation. ASK1 is a 170-kDa protein that is composed of an inhibitory
N-terminal domain, an internal kinase domain, and a C-terminal regulatory
domain. One important regulatory mechanism of ASK1 activity is its Ser/Thr
phosphorylation and dephosphorylation by kinases and phosphatases. ASK1 is
basally phosphorylated at Ser-967 by an unidentified kinase, and 14-3-3 binds
to this site and inhibits ASK1 activity
(11,
12). TNF activates ASK1 in
part by dissociating these cellular inhibitors from ASK1
(4,
7). Recently, we have
identified PP2A as a phosphatase in TNF-induced dephosphorylation of ASK1
Ser(P)-967 (13). In addition
to the 14-3-3-binding site, Ser(P)-967, ASK1 is phosphorylated at Ser-83 by
Akt, leading to inhibition of ASK1 activity. In contrast, autophosphorylation
of ASK1 at Thr-838 leads to oligomerization and activation
(14). Phosphorylation of
Thr-845 can be negatively regulated by the phosphatase PP5
(15). Similarly, we found that
the ASK1 autophosphorylation at Thr-813 and Thr-842 also positively regulates
ASK1 signaling (16).In contrast to Ser/Thr phosphorylation, regulation of ASK1 by tyrosine
phosphorylation is less well understood. We have recently shown that ASK1 is
phosphorylated at Tyr-718, and this phosphorylation is critical for the
binding to suppressor of cytokine signaling-1 (SOCS1), a subunit of ubiquitin
ligase responsible for ASK1 degradation
(17). Tyrosine phosphorylation
of ASK1 is up-regulated in response to growth factors and cytokines such as
IFN-γ, whereas this phosphorylation can be down-regulated by TNF
treatment, resulting in ASK1 dissociation from SOCS1. However, the kinase and
phosphatase responsible for phosphorylation and dephosphorylation of ASK1 at
Tyr-718 are not known.The cytoplasmic tyrosine kinase, JAK2, autophosphorylates in response to
growth factors and cytokines, including IFN-γ. JAK2 then activates
cytokine receptors and other cytoplasmic proteins such as the STATs by
phosphorylating their key tyrosine residue. The JAK/STAT pathway can be
regulated by SH2-containing protein-tyrosine phosphatases such as SHP2
(18–20).
SHP2 is ubiquitously expressed and composed of two SH2 domains on the
N-terminal and C-terminal protein-tyrosine phosphatase (PTP) domain. The SH2
domain of SHP2 mediates the association with phosphotyrosine-containing
proteins present on activated receptors as well as on activated JAKs and
STATs; this association triggers activation of the tyrosine phosphatase domain
and subsequent dephosphorylation of substrates. SHP2 signals downstream of
receptor tyrosine kinases and cytokine receptors, and in most cases it serves
to positively transduce signals from these receptors. In other instances SHP2
has been shown to exhibit inhibitory signaling properties by negatively
regulating the JAK-STAT pathway
(19).In this study, we demonstrate that the IFN-γ-activated kinase JAK2
and TNF-activated SHP2 are the tyrosine kinase and phosphatase for Tyr-718 on
ASK1, respectively. The actions of both JAK2 and SHP2 affect protein turnover
of ASK1 and thus regulate ASK1/JNK-dependent proinflammatory and proapoptotic
pathways in EC. 相似文献
8.
Shan Huang Jiqun Wang Hongbo Men Yi Tan Qian Lin Evelyne Gozal Yang Zheng Lu Cai 《Journal of cellular and molecular medicine》2021,25(14):6828-6840
To efficiently prevent diabetic cardiomyopathy (DCM), we have explored and confirmed that metallothionein (MT) prevents DCM by attenuating oxidative stress, and increasing expression of proteins associated with glucose metabolism. To determine whether Akt2 expression is critical to MT prevention of DCM, mice with either global Akt2 gene deletion (Akt2-KO), or cardiomyocyte-specific overexpressing MT gene (MT-TG) or both combined (MT-TG/Akt2-KO) were used. Akt2-KO mice exhibited symptoms of DCM (cardiac remodelling and dysfunction), and reduced expression of glycogen and glucose metabolism-related proteins, despite an increase in total Akt (t-Akt) phosphorylation. Cardiac MT overexpression in MT-TG/Akt2-KO mice prevented DCM and restored glucose metabolism-related proteins expression and baseline t-Akt phosphorylation. Furthermore, phosphorylation of ERK1/2 increased in the heart of MT-TG/Akt2-KO mice, compared with Akt2-KO mice. As ERK1/2 has been implicated in the regulation of glucose transport and metabolism this increase could potentially underlie MT protective effect in MT-TG/Akt2-KO mice. Therefore, these results show that although our previous work has shown that MT preserving Akt2 activity is sufficient to prevent DCM, in the absence of Akt2 MT may stimulate alternative or downstream pathways protecting from DCM in a type 2 model of diabetes, and that this protection may be associated with the ERK activation pathway. 相似文献
9.
Hongjuan Liao Weinian Gao Jie Ma Hongyuan Xue Yi Wang Dai Huang Fang Yan Yuquan Ye 《Cell biology international》2021,45(6):1211-1219
Hypertrophic growth of the cardiomyocytes is one of the core mechanisms underlying cardiac hypertrophy. However, the mechanism underlying cardiac hypertrophy remains not fully understood. Here we provided evidence that G protein-coupled receptor 39 (GPR39) promotes cardiac hypertrophy via inhibiting AMP-activated protein kinase (AMPK) signaling. GRP39 expression is overexpressed in hypertrophic hearts of humans and transverse aortic constriction (TAC)-induced cardiac hypertrophy in mice. In neonatal cardiomyocytes, adenovirus-mediated overexpression of GPR39 promoted angiotensin II-induced cardiac hypertrophy, while GPR39 knockdown repressed hypertrophic response. Adeno-associated virus 9-mediated knockdown of GPR39 suppressed TAC-induced decline in fraction shortening and ejection fraction, increase in heart weight and cardiomyocyte size, as well as overexpression of hypertrophic fetal genes. A mechanism study demonstrated that GPR39 repressed the activation of AMPK to activate the mammalian target of rapamycin (mTOR) and ribosomal protein S6 kinase β-1 (S6K1), subsequently promoted de novo protein synthesis. Inhibition of mTOR with rapamycin blocked the effects of GPR39 overexpression on protein synthesis and repressed cardiac hypertrophy. Collectively, our findings demonstrated that GPR39 promoted cardiac hypertrophy via regulating the AMPK–mTOR–S6K1 signaling pathway, and GRP39 can be targeted for the treatment of cardiac hypertrophy. 相似文献
10.
11.
Linmao Lyu Jiazheng Chen Wei Wang Tao Yan Jiamao Lin Hongmei Gao Hui Li Ruijuan Lv Feng Xu Lijun Fang Yuguo Chen 《Journal of cellular and molecular medicine》2021,25(6):3136-3148
Long-term poorly controlled myocardial hypertrophy often leads to heart failure and sudden death. Activation of ras-related C3 botulinum toxin substrate 1 (RAC1) by angiotensin II (Ang II) plays a pivotal role in myocardial hypertrophy. Previous studies have demonstrated that scoparone (SCO) has beneficial effects on hypertension and extracellular matrix remodelling. However, the function of SCO on Ang II-mediated myocardial hypertrophy remains unknown. In our study, a mouse model of myocardial hypertrophy was established by Ang II infusion (2 mg/kg/day) for 4 weeks, and SCO (60 mg/kg bodyweight) was administered by gavage daily. In vitro experiments were also performed. Our results showed that SCO could alleviate Ang II infusion-induced cardiac hypertrophy and fibrosis in mice. In vitro, SCO treatment blocks Ang II-induced cardiomyocyte hypertrophy, cardiac fibroblast collagen synthesis and differentiation to myofibroblasts. Meanwhile, we found that SCO treatment blocked Ang II-induced oxidative stress in cardiomyocytes and cardiac fibroblasts by inhibiting RAC1-GTP and total RAC1 in vivo and in vitro. Furthermore, reactive oxygen species (ROS) burst by overexpression of RAC1 completely abolished SCO-mediated protection in cardiomyocytes and cardiac fibroblasts in vitro. In conclusion, SCO, an antioxidant, may attenuate Ang II-induced myocardial hypertrophy by suppressing of RAC1 mediated oxidative stress. 相似文献
12.
Ying Huang Lianpin Wu Jian Wu Yumei Li Lili Hou 《Molecular and cellular biochemistry》2014,397(1-2):87-95
Cellular FLICE-like inhibitory protein (Flip) is a negative regulator of nuclear factor κB signaling which has been shown previously to complicate with cardiac hypertrophy. In the present study, we tested the hypothesis that the knockout of Flip would increase cardiac hypertrophy in vivo and in vitro. The effects of Flip knockout on cardiac hypertrophy were investigated using in vitro and in vivo models. Flip was downregulated in transverse aortic constriction (TAC)-induced animal hearts and cardiomyocytes that had been treated with angiotensin II or phenylephrine for 1 h. An in vivo, heart hypertrophy model, was performed by TAC in Flip knockdown and sham mice. The extent of hypertrophy of heart was quantitated by echocardiography, and further confirmed by pathological and molecular examination of heart tissue samples. Conditional knockout of Flip in the murine heart increases the hypertrophic response induced by TAC, whereas cardiac function was preserved with reduced Flip levels in response to hypertrophic stimuli. Western blot experiments further showed Flip knockout activated markedly ASK1/P38 signaling cascades in vivo and in vitro. In conclusion, Flip preserves cardiac functions and inhibits cardiac hypertrophy partially by blocking ASK1/P38 signaling. 相似文献
13.
Luo D He Y Zhang H Yu L Chen H Xu Z Tang S Urano F Min W 《The Journal of biological chemistry》2008,283(18):11905-11912
We have previously shown that ASK1-interacting protein 1 (AIP1) transduces tumor necrosis factor-induced ASK1-JNK signaling. Because endoplasmic reticulum (ER) stress activates ASK1-JNK signaling cascade, we investigated the role of AIP1 in ER stress-induced signaling. We created AIP1-deficient mice (AIP1-KO) from which mouse embryonic fibroblasts and vascular endothelial cells were isolated. AIP1-KO cells show dramatic reductions in ER stress-induced, but not oxidative stress-induced, ASK1-JNK activation and cell apoptosis. The ER stress-induced IRE1-JNK/XBP-1 axis, but not the PERK-CHOP1 axis, is blunted in AIP1-KO cells. ER stress induced formation of an AIP1-IRE1 complex, and the PH domain of AIP1 is critical for the IRE1 interaction. Furthermore, reconstitution of AIP1-KO cells with AIP1 wild type, not an AIP1 mutant with a deletion of the PH domain (AIP1-DeltaPH), restores ER stress-induced IRE1-JNK/XBP-1 signaling. AIP1-IRE1 association facilitates IRE1 dimerization, a critical step for activation of IRE1 signaling. More importantly, AIP1-KO mice show impaired ER stress-induced IRE1-dependent signaling in vivo. We conclude that AIP1 is essential for transducing the IRE1-mediated ER stress response. 相似文献
14.
15.
16.
Finsen AV Lunde IG Sjaastad I Østli EK Lyngra M Jarstadmarken HO Hasic A Nygård S Wilcox-Adelman SA Goetinck PF Lyberg T Skrbic B Florholmen G Tønnessen T Louch WE Djurovic S Carlson CR Christensen G 《PloS one》2011,6(12):e28302
Sustained pressure overload leads to compensatory myocardial hypertrophy and subsequent heart failure, a leading cause of morbidity and mortality. Further unraveling of the cellular processes involved is essential for development of new treatment strategies. We have investigated the hypothesis that the transmembrane Z-disc proteoglycan syndecan-4, a co-receptor for integrins, connecting extracellular matrix proteins to the cytoskeleton, is an important signal transducer in cardiomyocytes during development of concentric myocardial hypertrophy following pressure overload. Echocardiographic, histochemical and cardiomyocyte size measurements showed that syndecan-4(-/-) mice did not develop concentric myocardial hypertrophy as found in wild-type mice, but rather left ventricular dilatation and dysfunction following pressure overload. Protein and gene expression analyses revealed diminished activation of the central, pro-hypertrophic calcineurin-nuclear factor of activated T-cell (NFAT) signaling pathway. Cardiomyocytes from syndecan-4(-/-)-NFAT-luciferase reporter mice subjected to cyclic mechanical stretch, a hypertrophic stimulus, showed minimal activation of NFAT (1.6-fold) compared to 5.8-fold increase in NFAT-luciferase control cardiomyocytes. Accordingly, overexpression of syndecan-4 or introducing a cell-permeable membrane-targeted syndecan-4 polypeptide (gain of function) activated NFATc4 in vitro. Pull-down experiments demonstrated a direct intracellular syndecan-4-calcineurin interaction. This interaction and activation of NFAT were increased by dephosphorylation of serine 179 (pS179) in syndecan-4. During pressure overload, phosphorylation of syndecan-4 was decreased, and association between syndecan-4, calcineurin and its co-activator calmodulin increased. Moreover, calcineurin dephosphorylated pS179, indicating that calcineurin regulates its own binding and activation. Finally, patients with hypertrophic myocardium due to aortic stenosis had increased syndecan-4 levels with decreased pS179 which was associated with increased NFAT activation. In conclusion, our data show that syndecan-4 is essential for compensatory hypertrophy in the pressure overloaded heart. Specifically, syndecan-4 regulates stretch-induced activation of the calcineurin-NFAT pathway in cardiomyocytes. Thus, our data suggest that manipulation of syndecan-4 may provide an option for therapeutic modulation of calcineurin-NFAT signaling. 相似文献
17.
Resistin has been suggested to be involved in the development of diabetes and insulin resistance. We recently reported that resistin is expressed in diabetic hearts and promotes cardiac hypertrophy; however, the mechanisms underlying this process are currently unknown. Therefore, we wanted to elucidate the mechanisms associated with resistin-induced cardiac hypertrophy and myocardial insulin resistance. Overexpression of resistin using adenoviral vector in neonatal rat ventricular myocytes was associated with inhibition of AMP-activated protein kinase (AMPK) activity, activation of tuberous sclerosis complex 2/mammalian target of rapamycin (mTOR) pathway, and increased cell size, [(3)H]leucine incorporation (i.e. protein synthesis) and mRNA expression of the hypertrophic marker genes, atrial natriuretic factor, brain natriuretic peptide, and β-myosin heavy chain. Activation of AMPK with 5-aminoimidazole-4-carbozamide-1-β-D-ribifuranoside or inhibition of mTOR with rapamycin or mTOR siRNA attenuated these resistin-induced changes. Furthermore, resistin increased serine phosphorylation of insulin receptor substrate (IRS1) through the activation of the apoptosis signal-regulating kinase 1/c-Jun N-terminal Kinase (JNK) pathway, a module known to stimulate insulin resistance. Inhibition of JNK (with JNK inhibitor SP600125 or using dominant-negative JNK) reduced serine 307 phosphorylation of IRS1. Resistin also stimulated the activation of p70(S6K), a downstream kinase target of mTOR, and increased phosphorylation of the IRS1 serine 636/639 residues, whereas treatment with rapamycin reduced the phosphorylation of these residues. Interestingly, these in vitro signaling pathways were also operative in vivo in ventricular tissues from adult rat hearts overexpressing resistin. These data demonstrate that resistin induces cardiac hypertrophy and myocardial insulin resistance, possibly via the AMPK/mTOR/p70(S6K) and apoptosis signal-regulating kinase 1/JNK/IRS1 pathways. 相似文献
18.
19.
Adrenergic regulation of cardiac myocyte apoptosis. 总被引:5,自引:0,他引:5
K Singh L Xiao A Remondino D B Sawyer W S Colucci 《Journal of cellular physiology》2001,189(3):257-265
The direct effects of catecholamines on cardiac myocytes may contribute to both normal physiologic adaptation and pathologic remodeling, and may be associated with cellular hypertrophy, apoptosis, and alterations in contractile function. Norepinephrine (NE) signals via alpha- and beta-adrenergic receptors (AR) that are coupled to G-proteins. Pharmacologic studies of cardiac myocytes in vitro demonstrate that stimulation of beta1-AR induces apoptosis which is cAMP-dependent and involves the voltage-dependent calcium influx channel. In contrast, stimulation of beta2-AR exerts an anti-apoptotic effect which appears to be mediated by a pertussis toxin-sensitive G protein. Stimulation of alpha1-AR causes myocyte hypertrophy and may exert an anti-apoptotic action. In transgenic mice, myocardial overexpression of either beta1-AR or G(alpha)s is associated with myocyte apoptosis and the development of dilated cardiomyopathy. Myocardial overexpression of beta2-AR at low levels results in improved cardiac function, whereas expression at high levels leads to dilated cardiomyopathy. Overexpression of wildtype alpha1B-AR does not result in apoptosis, whereas overexpression of G(alpha)q results in myocyte hypertrophy and/or apoptosis depending on the level of expression. Differential activation of the members of the mitogen-activated protein kinase (MAPK) superfamily and production of reactive oxygen species appear to play a key role in mediating the actions of adrenergic pathways on myocyte apoptosis and hypertrophy. This review summarizes current knowledge about the molecular and cellular mechanisms involved in the regulation of cardiac myocyte apoptosis via stimulation of adrenergic receptors and their coupled effector pathways. 相似文献
20.
Irene Pérez López Luca Cariolato Darko Maric Ludovic Gillet Hugues Abriel Dario Diviani 《Molecular and cellular biology》2013,33(15):2903-2917
In response to stress, the heart undergoes a remodeling process associated with cardiac hypertrophy that eventually leads to heart failure. A-kinase anchoring proteins (AKAPs) have been shown to coordinate numerous prohypertrophic signaling pathways in cultured cardiomyocytes. However, it remains to be established whether AKAP-based signaling complexes control cardiac hypertrophy and remodeling in vivo. In the current study, we show that AKAP-Lbc assembles a signaling complex composed of the kinases PKN, MLTK, MKK3, and p38α that mediates the activation of p38 in cardiomyocytes in response to stress signals. To address the role of this complex in cardiac remodeling, we generated transgenic mice displaying cardiomyocyte-specific overexpression of a molecular inhibitor of the interaction between AKAP-Lbc and the p38-activating module. Our results indicate that disruption of the AKAP-Lbc/p38 signaling complex inhibits compensatory cardiomyocyte hypertrophy in response to aortic banding-induced pressure overload and promotes early cardiac dysfunction associated with increased myocardial apoptosis, stress gene activation, and ventricular dilation. Attenuation of hypertrophy results from a reduced protein synthesis capacity, as indicated by decreased phosphorylation of 4E-binding protein 1 and ribosomal protein S6. These results indicate that AKAP-Lbc enhances p38-mediated hypertrophic signaling in the heart in response to abrupt increases in the afterload. 相似文献